Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta
- 10 April 2007
- journal article
- research article
- Published by Elsevier in Journal of Immunological Methods
- Vol. 321 (1-2) , 19-31
- https://doi.org/10.1016/j.jim.2006.12.012
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Guidelines on use of anti‐IFN‐β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐β antibodies in multiple sclerosisEuropean Journal of Neurology, 2005
- The importance of measuring IFNβ bioactivity: Monitoring in MS patients and the effect of anti-IFNβ antibodiesJournal of Neuroimmunology, 2005
- Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genesLaboratory Investigation, 2005
- Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodiesJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Neutralizing antibodies against IFN- in multiple sclerosis: antagonization of IFN- mediated suppression of MMPsBrain, 2004
- A Novel Bioassay for the Determination of Neutralizing Antibodies to IFNβ1bJournal of Interferon & Cytokine Research, 1998
- A Novel Sensitive and Selective Bioassay for Human Type I InterferonsJournal of Interferon & Cytokine Research, 1998
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- The log transformation is specialStatistics in Medicine, 1995
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 1986